About Heron Therapeutics
Heron Therapeutics is a company based in Redwood City (United States) founded in 1983. It operates as a Direct-to-Consumer (D2C). Heron Therapeutics has raised $32.14 million across 10 funding rounds from investors including Hercules Capital, Rubric Capital and Velan Capital. The company has 122 employees as of December 31, 2024. Heron Therapeutics offers products and services including SUSTOL, CINVANTI, ZYNRELEF, and APONVIE. Heron Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Redwood City, United States
- Employees 122 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Heron Therapeutics, Inc.
-
Annual Revenue
$144.28 M (USD)13.57as on Dec 31, 2024
-
Net Profit
-$13.58 M (USD)87.72as on Dec 31, 2024
-
EBITDA
-$9.04 M (USD)91.61as on Dec 31, 2024
-
Total Equity Funding
$32.14 M (USD)
in 10 rounds
-
Latest Funding Round
$30 M (USD), Post-IPO
Jul 24, 2023
-
Investors
Hercules Capital
& 6 more
-
Employee Count
122
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Heron Therapeutics
Heron Therapeutics is a publicly listed company on the NASDAQ with ticker symbol HRTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Heron Therapeutics
Heron Therapeutics offers a comprehensive portfolio of products and services, including SUSTOL, CINVANTI, ZYNRELEF, and APONVIE.
Used for preventing chemotherapy-induced nausea and vomiting.
Administered to prevent nausea and vomiting from chemotherapy.
Designed for managing postoperative pain in patients.
Utilized for preventing postoperative nausea and vomiting.
People of Heron Therapeutics
Unlock access to complete
Unlock access to complete
Software Development Team
29 people
Leadership Team
24 people
Sales and Marketing
8 people
Finance and Accounting
4 people
Operations Team
3 people
Legal and Compliance
3 people
Human Resources and Administration
2 people
Senior Team
2 people
Unlock access to complete
Funding Insights of Heron Therapeutics
Heron Therapeutics has successfully raised a total of $32.14M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Heron Therapeutics
Heron Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Hercules Capital, Rubric Capital and Velan Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Clearline Capital, LLC is engaged in emerging market debt solutions.
|
Locked | Locked | Locked | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked |
Investor details for Heron Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Heron Therapeutics
Investment portfolio details for Heron Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Heron Therapeutics
Detailed financials for Heron Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Heron Therapeutics Comparisons
Peer comparison for Heron Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Heron Therapeutics
Heron Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Heron Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Heron Therapeutics
Complete news archive for Heron Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Heron Therapeutics
Heron Therapeutics was founded in 1983 and raised its 1st funding round 26 years after it was founded.
Heron Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Heron Therapeutics is a funded company, having raised a total of $32.14M across 10 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Heron Therapeutics is 122.
Annual revenue of Heron Therapeutics is $144.28M as on Dec 31, 2024.
Heron Therapeutics is dedicated to advancing therapeutic standards for patients through innovative science and technologies. The company is engaged in developing and commercializing a portfolio of best-in-class therapies aimed at addressing unmet medical needs in acute care and oncology sectors. Solutions such as SUSTOL, CINVANTI, ZYNRELEF, and APONVIE are provided to prevent issues like chemotherapy-induced nausea, vomiting, and postoperative pain. The focus is placed on improving patient outcomes by rethinking treatment approaches and reducing reliance on opioids in surgical settings.
Heron Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Heron Therapeutics offers SUSTOL, CINVANTI, ZYNRELEF, and APONVIE.
Yes, Heron Therapeutics is publicly traded on NASDAQ under the ticker symbol HRTX.
Heron Therapeutics has 7 investors. Key investors include Hercules Capital, Rubric Capital, Velan Capital, Clearline Capital, and Deep Track Capital.
The ticker symbol of Heron Therapeutics is HRTX on NASDAQ.